vTv Therapeutics to Engage in Virtual HCW@Home Event Soon
vTv Therapeutics to Engage in Virtual HCW@Home Event Soon
HIGH POINT, N.C. – vTv Therapeutics Inc. (NASDAQ: VTVT), a biopharmaceutical firm at the forefront of diabetes treatment, is excited to share its upcoming participation in the H.C. Wainwright “HCW@Home” Series, taking place virtually. This event is a great opportunity for the company to discuss its innovative approach to managing type 1 diabetes (T1D) through its investigational drug cadisegliatin.
Event Highlights
The “HCW@Home with vTv Therapeutics” event is set for an engaging fireside chat format. The discussion will be moderated by Emily Bodnar, who is the Director at H.C. Wainwright. vTv Therapeutics will feature key personnel, offering insights into their mission and pipeline.
Featured Speakers
Attendees will hear from distinguished voices within vTv Therapeutics, including:
- Paul Sekhri, who serves as Chairman of the Board, President, and CEO
- Thomas Strack, MD, Chief Medical Officer
- Carmen Valcarce, Ph.D., Executive Vice President and Chief Scientific Officer
- Michael Tung, MD, MBA, Chief Financial Officer
This varied team brings together expertise across fields, demonstrating vTv's commitment to advancing medical science.
Event Timing and Access
The event will occur on Thursday, June 12, starting at 10:00 AM ET. Interested individuals may register online to join this informative session. The company will archive the webcast on its official News & Events page, providing a resource for those unable to attend live.
About vTv Therapeutics
vTv Therapeutics Inc. is dedicated to developing oral therapies targeting chronic diseases, specifically aimed at supporting individuals living with diabetes. Currently, its clinical pipeline is highlighted by cadisegliatin, a cutting-edge glucokinase activator in Phase 3 trials aimed at treating type 1 diabetes. In addition to cadisegliatin, vTv is exploring various molecules targeting multiple indications to address the needs of chronic disease patients.
Corporate Engagement
To stay informed about vTv's latest initiatives and developments, you can follow the company on LinkedIn or visit their website. Engagement with the community helps build a brighter future for patients living with chronic diseases.
Investor Information
If you're an investor or media professional seeking further information, please reach out to the contacts listed below:
Investor ContactJohn Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
Frequently Asked Questions
What is cadisegliatin?
Cadisegliatin is a potential first-in-class oral adjunctive therapy to insulin, currently being investigated for treating type 1 diabetes.
When will the HCW@Home event take place?
The event is scheduled for Thursday, June 12, at 10:00 AM ET.
Who will be speaking at the event?
Key executives including Paul Sekhri, Thomas Strack, and Carmen Valcarce among others will present insights at the event.
How can I access the event?
You can register online for the event, and it will also be available for viewing on vTv's website afterward.
What is vTv Therapeutics focused on?
vTv Therapeutics is focused on developing innovative therapies for chronic diseases, particularly emphasizing treatments for diabetes.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
